These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 17241709)
1. Prophylactic potential of liposomized integral membrane protein of Plasmodium yoelii nigeriensis against blood stage infection in BALB/c mice. Sharma SK; Gupta C; Dwivedi V; Misra-Bhattacharya S; Mohammad O Vaccine; 2007 Mar; 25(11):2103-11. PubMed ID: 17241709 [TBL] [Abstract][Full Text] [Related]
2. Escheriosome entrapped soluble blood stage antigens impart protective immunity against a multi-drug resistant isolate of Plasmodium yoelii nigeriensis in BALB/c mice. Sharma SK; Farah D; Misra-Bhattacharya S; Bajpai P; Agarwal A; Mohammad O Vaccine; 2006 Feb; 24(7):948-56. PubMed ID: 16168527 [TBL] [Abstract][Full Text] [Related]
3. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge. Wang L; Goschnick MW; Coppel RL Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Wang L; Webster DE; Campbell AE; Dry IB; Wesselingh SL; Coppel RL Int J Parasitol; 2008 Jan; 38(1):103-10. PubMed ID: 17681344 [TBL] [Abstract][Full Text] [Related]
5. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice. Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232 [TBL] [Abstract][Full Text] [Related]
7. Fc receptors are not required for antibody-mediated protection against lethal malaria challenge in a mouse model. Rotman HL; Daly TM; Clynes R; Long CA J Immunol; 1998 Aug; 161(4):1908-12. PubMed ID: 9712060 [TBL] [Abstract][Full Text] [Related]
8. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Rotman HL; Daly TM; Long CA Exp Parasitol; 1999 Jan; 91(1):78-85. PubMed ID: 9920045 [TBL] [Abstract][Full Text] [Related]
9. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. Daly TM; Long CA J Immunol; 1995 Jul; 155(1):236-43. PubMed ID: 7602100 [TBL] [Abstract][Full Text] [Related]
10. [Protective immune mechanisms induced by cellular vaccine made of the erythrocytic Plasmodium yoelii]. Yuan J; Xu B; Liu BF Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):47-51. PubMed ID: 15052774 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice. Sanchez GI; Sedegah M; Rogers WO; Jones TR; Sacci J; Witney A; Carucci DJ; Kumar N; Hoffman SL Infect Immun; 2001 Jun; 69(6):3897-905. PubMed ID: 11349057 [TBL] [Abstract][Full Text] [Related]
12. Identification of karyopherin beta as an immunogenic antigen of the malaria parasite using immune mice and human sera. Mohmmed A; Kishore S; Patra KP; Dasaradhi PV; Malhotra P; Chauhan VS Parasite Immunol; 2005 May; 27(5):197-203. PubMed ID: 15987343 [TBL] [Abstract][Full Text] [Related]
13. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1. Hirunpetcharat C; Vukovic P; Liu XQ; Kaslow DC; Miller LH; Good MF J Immunol; 1999 Jun; 162(12):7309-14. PubMed ID: 10358180 [TBL] [Abstract][Full Text] [Related]
14. Adjuvanticity and protective immunity of Plasmodium yoelii nigeriensis blood-stage soluble antigens encapsulated in fusogenic liposome. Dwivedi V; Vasco A; Vedi S; Dangi A; Arif K; Bhattacharya SM; Owais M Vaccine; 2009 Jan; 27(3):473-82. PubMed ID: 18996429 [TBL] [Abstract][Full Text] [Related]
15. Active immunisation with RAMA does not provide protective immunity against Plasmodium yoelii challenge despite its association with protective responses in endemic populations. Kats LM; Wang L; Murhandarwati EE; Mitri K; Black CG; Coppel RL Vaccine; 2008 Jun; 26(26):3261-7. PubMed ID: 18468741 [TBL] [Abstract][Full Text] [Related]
16. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Goschnick MW; Black CG; Kedzierski L; Holder AA; Coppel RL Infect Immun; 2004 Oct; 72(10):5840-9. PubMed ID: 15385485 [TBL] [Abstract][Full Text] [Related]
17. Active and passive immunization against Plasmodium yoelii sporozoites. Charoenvit Y; Sedegah M; Yuan LF; Gross M; Cole C; Bechara R; Leef MF; Robey FA; Lowell GH; Beaudoin RL Bull World Health Organ; 1990; 68 Suppl(Suppl):26-32. PubMed ID: 1709834 [TBL] [Abstract][Full Text] [Related]
18. Plasmodium yoelii blood-stage antigens newly identified by immunoaffinity using purified IgG antibodies from malaria-resistant mice. Kamali AN; Marín-García P; Azcárate IG; Diez A; Puyet A; Bautista JM Immunobiology; 2012 Aug; 217(8):823-30. PubMed ID: 22658767 [TBL] [Abstract][Full Text] [Related]
19. Plasmodium yoelii: the role of the individual epidermal growth factor-like domains of the merozoite surface protein-1 in protection from malaria. Calvo PA; Daly TM; Long CA Exp Parasitol; 1996 Jan; 82(1):54-64. PubMed ID: 8617331 [TBL] [Abstract][Full Text] [Related]
20. Serum antibody immunoglobulin G of mice convalescent from Plasmodium yoelii infection inhibits growth of Plasmodium falciparum in vitro: blood stage antigens of P. falciparum involved in interspecies cross-reactive inhibition of parasite growth. Ray P; Sahoo N; Singh B; Kironde FA Infect Immun; 1994 Jun; 62(6):2354-61. PubMed ID: 8188358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]